Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

B Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena…
posteditor
posteditor
Articles: 21727

Other News